Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/32101
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Klein, Oliver | - |
dc.contributor.author | Kee, Damien | - |
dc.contributor.author | Nagrial, Adnan | - |
dc.contributor.author | Markman, Ben | - |
dc.contributor.author | Underhill, Craig | - |
dc.contributor.author | Michael, Michael | - |
dc.contributor.author | Behren, Andreas | - |
dc.contributor.author | Palmer, Jodie | - |
dc.contributor.author | Tebbutt, Niall C | - |
dc.contributor.author | Carlino, Matteo S | - |
dc.contributor.author | Cebon, Jonathan S | - |
dc.date | 2023 | - |
dc.date.accessioned | 2023-02-07T05:52:06Z | - |
dc.date.available | 2023-02-07T05:52:06Z | - |
dc.date.issued | 2023-04-01 | - |
dc.identifier.citation | Cancer 2023-04-01; 129(7) | - |
dc.identifier.issn | 1097-0142 | - |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/32101 | - |
dc.language.iso | eng | - |
dc.title | Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers? | - |
dc.type | Journal Article | - |
dc.identifier.journaltitle | Cancer | - |
dc.identifier.affiliation | Medical Oncology | - |
dc.identifier.affiliation | Blacktown Hospital, Blacktown, New South Wales, Australia. | - |
dc.identifier.affiliation | Department of Medical Oncology, Alfred Health, Prahran, Victoria, Australia. | - |
dc.identifier.affiliation | Albury-Wodonga Regional Cancer Centre, Albury-Wodonga, New South Wales, Australia. | - |
dc.identifier.affiliation | Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. | - |
dc.identifier.affiliation | Olivia Newton-John Cancer Research Institute | - |
dc.identifier.affiliation | Blacktown Hospital, Blacktown, New South Wales, Australia. | - |
dc.identifier.doi | 10.1002/cncr.34660 | - |
dc.type.content | Text | - |
dc.identifier.orcid | 0000-0003-0022-9553 | - |
dc.identifier.pubmedid | 36692958 | - |
dc.description.volume | 129 | - |
dc.description.issue | 7 | - |
dc.description.startpage | 1129 | - |
dc.description.endpage | 1130 | - |
dc.subject.meshtermssecondary | Antibodies, Monoclonal/therapeutic use | - |
local.name.researcher | Cebon, Jonathan S | |
item.openairetype | Journal Article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.languageiso639-1 | en | - |
crisitem.author.dept | Medical Oncology | - |
crisitem.author.dept | Medical Oncology | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
crisitem.author.dept | Medical Oncology | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.